We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Physician Office IVD Sector Nears USD 2.5 Billion

By LabMedica International staff writers
Posted on 14 Sep 2014
The physician office laboratory (POL) in vitro diagnostic (IVD) market grew to USD 2.44 billion in 2013, from just over USD 2 billion four years ago, according to the 2014 market study report “Physician Office Laboratory Markets, 3rd Edition” from Kalorama Information (New York, NY, USA). More...
Considered in its POL analysis are tests physically performed in a physician office setting or lab located on the premises of the clinic or practice (not an associated hospital), and performed at the time of a consultation with a physician or other healthcare professional for screening, diagnosis, or monitoring purposes.

Physician Office Laboratory Markets reveals that unlike laboratory medicine (or lab pathology), there is no settled role for professional point-of-care (POC) or “near-patient” testing (NPT) in modern healthcare systems. The use of decentralized IVD testing in primary and outpatient care, most often in POLs, is not uniform worldwide nor is it universally supported. Nonetheless, payers, regulators, and administrators are forced to address POL testing as capabilities of benchtop and portable IVD instruments and assays improve and present clinicians with more in-house testing options.

"Gone are the days when professional POC diagnostics markets could aspire to above-average annual revenue on the basis of market penetration and the rising profile of decentralized testing," said Emil Salazar, analyst for Kalorama Information and author of the report, "The overall POL market is instead projected over the next 5 years to average growth near equal with the overall global IVD market."

The POL market features numerous in-office tests that have been widely implemented due to the low hurdles presented by CLIA-waived testing and the value of core lab tests performed in-office at large practices and with specialists. Some POL test segments are expected to see average annual growth through 2019 of only 0%–1%. POL test segments projected to attract more growth (rates of 5% and over) are related to diabetes care, cardiovascular disease, and actionable infectious disease markers. Routine infectious disease testing has also invited the first forays of molecular diagnostics into the POL space.

The prospects of POL market growth also vary widely by geography. Kalorama Information has profiled the traditionally core country markets for POL tests and determined their future potential in light of recent regulatory tightening of fee schedules and reimbursement eligibility as well as other factors. In some cases, recent regulation threatens to tip competitive balance even more towards higher-volume labs, typically reference or commercial labs, across from smaller labs including POLs.

Physician Office Laboratory Markets not only presents leading opportunities for IVD sales growth in the POL channel, but is also a valuable resource for determining competitive positioning within the channel vis-à-vis its leading players.

Related Links:

Kalorama Information



Gold Member
Serological Pipets
INTEGRA Serological Pipets
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.